AirSculpt Technologies, Inc. provides premium body contouring procedures through AirSculpt offices. Its AirSculpt method is a minimally invasive treatment for fat removal, skin tightening, targeted body sculpting, and fat transfer procedures that use a patient’s own fat cells.
Company news centers on operating results, same-center and same-store sales trends, case volume, revenue, adjusted EBITDA, guidance, marketing initiatives, new procedure categories, balance sheet activity, and governance changes. Updates also address the company’s positioning within aesthetics demand tied to GLP-1 use and its direct medical procedure services model.
AirSculpt Technologies (NASDAQ:AIRS) reported fourth-quarter and full-year fiscal 2025 results, with revenue of $33.4M in Q4 and $151.8M for full-year 2025. Case volume declined ~15% year-over-year to 2,604 in Q4 and 11,852 for 2025. Full-year adjusted EBITDA was $15.1M and net loss was $11.7M. The company issued 2026 guidance of $151–$157M revenue and $15–$17M adjusted EBITDA. As of Dec 31, 2025 cash was $8.4M, gross debt ~$56M, with subsequent ATM proceeds of $14.8M and debt reduced to ~$45M.
AirSculpt set its annual meeting for May 12, 2026 and will host a conference call on April 2, 2026.
AirSculpt Technologies (NASDAQ: AIRS) will report fourth quarter and fiscal year 2025 results before market open on Thursday, April 2, 2026, followed by a conference call at 8:30 a.m. Eastern Time the same day.
Investors may join by domestic toll-free dial-in, international dial-in with conference ID 13758597, or via the live webcast in the investor relations section. A replay will be available for approximately 90 days.
AirSculpt (NASDAQ:AIRS) expects to file a Form 12b-25 on March 16, 2026, to delay its Form 10-K filing for the year ended December 31, 2025, by 15 days while it completes classification of inter-company transactions and balances.
Preliminary fiscal 2025 revenue was $151.8 million, Q4 2025 preliminary revenue was $33.4 million, Q1 2026 revenue is estimated at $38.5–$39.5 million, cash was $13.0 million and debt $46.0 million. Same-store sales improved in February 2026.
AirSculpt Technologies (NASDAQ:AIRS) announced on November 17, 2025 that Mike Doyle has been appointed Non-Executive Chairman of the company's board.
Mr. Doyle brings over 30 years of multi-center healthcare leadership and recent private-equity and operating experience, including roles as Managing Partner of Vesey Street Capital Partners since January 2025, founder and CEO of MD Healthcare Partners (2018–Dec 2024), and CEO of Surgery Partners (2009–Sept 2017) where he helped scale the business from 3 to over 175 locations.
The appointment highlights board-level reinforcement as AirSculpt pursues its next phase of transformation and leverages Doyle's experience with multi-site operations and surgeon partnerships.
AirSculpt Technologies (NASDAQ:AIRS) reported third quarter fiscal 2025 results on November 7, 2025. Q3 revenue declined to $35.0M (down 17.8% YoY) and case volume fell to 2,780 (down 15.2% YoY). The company posted a Q3 net loss of $9.5M and Adjusted EBITDA of $3.0M.
Year-to-date through nine months, revenue was $118.4M (down 16.1%), net loss $13.0M, and Adjusted EBITDA $12.6M. AirSculpt lowered full-year 2025 revenue guidance to ~$153M and set Adjusted EBITDA at ~$16M. Liquidity included $5.4M cash and $5.0M revolver capacity; the company reduced debt by $18M and reported positive operating cash flow year-to-date.
AirSculpt Technologies (NASDAQ: AIRS) will report third quarter 2025 financial results before market open on Friday, November 7, 2025.
The company will host a conference call the same day at 8:30 a.m. Eastern Time. Dial-in numbers are 1-877-407-9716 (toll-free U.S.) and 1-201-493-6779 (international) using conference ID 13756042. Investors can also request an instant return call or join the live webcast via the investor relations site at https://investors.airsculpt.com.
A replay of the webcast will be available for approximately 90 days.
AirSculpt Technologies (NASDAQ:AIRS), a national provider of premium body contouring procedures, has announced its participation in the upcoming Sidoti Micro Cap Conference, which will be held virtually from August 20-21, 2025.
The company's management team will conduct investor meetings throughout the conference and deliver a presentation on Wednesday, August 20 at 10:00am ET. Investors can access the live webcast through the company's investor relations website, with the presentation recording remaining available for 90 days.
AirSculpt Technologies (NASDAQ:AIRS), a premium body contouring provider, reported Q2 2025 results showing revenue decline of 13.7% to $44.0 million compared to Q2 2024. The company posted a net loss of $0.6 million, improved from a $3.2 million loss in Q2 2024. Case volume decreased by 14.1% to 3,392 cases.
The company announced two strategic initiatives: a pilot program for skin tightening services targeting GLP-1 users, and expanded financing options. Additionally, AirSculpt reduced its debt by $16 million following a successful common stock offering in June 2025.
The company maintained its full-year 2025 guidance of $160-170 million in revenue and $16-18 million in Adjusted EBITDA. CFO Dennis Dean announced his retirement but will remain until a successor is appointed.
AirSculpt Technologies (NASDAQ: AIRS), a premium body contouring procedures provider, has scheduled its second quarter 2025 financial results announcement for Friday, August 1, 2025. The company will release results before market open, followed by a conference call at 8:30 a.m. Eastern Time.
Investors can access the conference call through multiple channels, including toll-free domestic (1-877-407-9716) and international (1-201-493-6779) numbers with conference ID 13754561. A live webcast will be available on the company's investor relations website, with the replay accessible for approximately 90 days.